A novel codon insert in protease of clade B HIV type 1. by Jordan, Parris S et al.
Thomas Jefferson University
Jefferson Digital Commons
Division of Infectious Diseases and Environmental
Medicine Sidney Kimmel Medical College
5-1-2009
A novel codon insert in protease of clade B HIV
type 1.
Parris S Jordan
University of California, San Diego
Art Poon
University of California, San Diego
Joseph Eron
University of North Carolina at Chapel Hill
Kathleen Squires
Division of Infectious Diseases and Environmental Medicine, Thomas Jefferson University
Caroline Ignacio
University of California, San Diego
See next page for additional authors
Let us know how access to this document benefits you
Follow this and additional works at: http://jdc.jefferson.edu/didem
Part of the Infectious Disease Commons
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas
Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly
publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and
interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in
Division of Infectious Diseases and Environmental Medicine by an authorized administrator of the Jefferson Digital Commons. For more information,
please contact: JeffersonDigitalCommons@jefferson.edu.
Recommended Citation
Jordan, Parris S; Poon, Art; Eron, Joseph; Squires, Kathleen; Ignacio, Caroline; Richman, Douglas D;
and Smith, Davey M, "A novel codon insert in protease of clade B HIV type 1." (2009). Division of
Infectious Diseases and Environmental Medicine. Paper 3.
http://jdc.jefferson.edu/didem/3
Authors
Parris S Jordan, Art Poon, Joseph Eron, Kathleen Squires, Caroline Ignacio, Douglas D Richman, and Davey
M Smith
This article is available at Jefferson Digital Commons: http://jdc.jefferson.edu/didem/3
Sequence Note
A Novel Codon Insert in Protease of Clade B HIV Type 1
Parris S. Jordan,1 Art Poon,1 Joseph Eron,2 Kathleen Squires,3 Caroline Ignacio,1
Douglas D. Richman,1,4 and Davey M. Smith1,4
Abstract
A novel combination of three codon inserts in the pol coding region of HIV-1 RNA was identified in a highly
antiretroviral experienced study subject with HIV-1 infection. A one codon insert was observed in the protease
region between codon 40 and 41 simultaneouslywith a two codon insert present in the reverse transcriptase region
at codon 69.
The objective of HIV treatment is to suppress viralreplication, and currently more than 20 different drugs
have been approved to treat HIV.1 Shortly after antiretroviral
drugs were in clinical trial, drug resistance-associated muta-
tions were first described.2 HIV drug resistance has since
been described for every active drug3 and drug resistance
testing has been incorporated as part of standard clinical
management and clinical trial design.4 In the course of a
clinical study to assess the treatment of protease-resistant
virus we discovered a previously unreported three base in-
sert in HIV-1 clade B protease (PR) simultaneously with a six
base insert in reverse transcriptase (RT) (GenBank accession
number FJ159426).
HIV RNAwas extracted, reverse transcribed, and the poly-
merase (pol) gene was amplified according to the manufac-
turer’s instructions using the ViroSeq HIV-1 Genotyping
System Version 2.0 (Celera Diagnostics, Foster City, CA).
Sequence data were analyzed using ViroSeq Version 2.6 Se-
quence Analysis Software (Celera Diagnostics).
The six nucleotide insert (Fig. 1A) has been described pre-
viously and is known as a T69SþXX insertion.5 These inserts
usually have a ‘‘T’’-to-‘‘S’’ point mutation at codon 69 and then
a two amino acid insertion added to the functional protein.
The proposed mechanism of decreasing susceptibility to ART
by this insertion is to stall or to cause the slippage of RT during
reverse transcription.6 Virus isolates containing these inser-
tions have reduced susceptibility to all nucleoside and nu-
cleotide RT inhibitors.7 Stalling or slippage has also been
hypothesized to be the mechanism behind the generation of
PR inserts. Several PR insert strains have been identified both
with and without major PR resistance mutations, although
these PR inserts have not been shown to directly contribute to
decreased susceptibility to protease inhibitors (PI).8 The insert
we describe (Fig.1B) has not yet been evaluated with site-
directed mutants with and without the associated PI resis-
tance mutations for impact on PI susceptibility in vitro. This
insert, however, was identified in the setting of extensive,
prolonged, and intermittent ART pressure (Fig. 2). The anti-
retroviral susceptibility profiles of the viruses with these in-
serts using the Monogram Phenosense assay are shown in
Table 1.
To model the function of the described PR insert, we gen-
erated superimposed computer models of PR with or with-
out our specific insert (Fig. 3). The close proximity of the one
codon insert to the functional binding cleft of the PR homo-
dimer could impact drug susceptibility, since the morphology
and nature of the binding cleft may be altered by the addition
of amino acids extending near or into the binding site leading
to decreased PI binding.9 Further in vitro characterization of
this novel PR insert with and without corresponding PR
mutations associated with decreased susceptibility to PI still
need to be evaluated.
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FIG. 1. (A) Electropherogram of the two codon RT insert. The arrow highlights the position of the additional bases. The
consensus sequence is located on top of the patient sequence. Also shown are the three different primers (labeled 1, 2, and 3)
that provided coverage for this coding region. (B) Electropherogram of the PR codon insert. The arrow highlights the position
of the additional bases. The consensus sequence is located on top of the patient sequence and the three different primers
(labeled 1, 2, and 3) that provided coverage for this region are shown.
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FIG. 2. Patient medication history, CD4 counts, and HIV viral load. Black diamonds are viral loads, open squares are CD4
counts, and double-headed arrows cover the dates of prescribed antiretroviral therapy [AZT, zidovudine; 3TC, lamivudine;
IND, indinavir; SQV, saquinavir; D4T, stavudine; EFV, efavirez; DDI, didianosine; NLF, nelfinavir; ABC, abacavir; APV,
amprenavir; RTV, ritonovir; LPV=R, kaletra (lopinavirþ ritonovir); TDF, tenofovir; AMP, amprenavir; TVZ, trizivir (zidovudineþ
lamivudineþ abacavir)].
Table 1. Phenotypic Data October 2003
Using the Monogram Phenosense Assay
Abbreviation Medication name
Fold change in
IC50: Phenosense
NRTIs
AZT, ZDV Zidovudine 26.0
3TC Lamivudine >Max
D4T Stavudine 5.2
DDI Didianosine 4.4
ABC, ABV Abacavir 25.0
DDC Zalcitabine 479.0
TDF Tenofovir 285.0
NNRTIs
DLV Delaviridine >Max
EFV Efavirez >Max
NVP Nevirapine 36.0
PIs
LPV=r Lopinavir >Max
IDV Indinavir 103.0
SQV Saquinavir 29.0
RTV Ritonovir >Max
APV Amprenavir 62.0
NFV Nelfinavir 66.0
FIG. 3. Energy minimized computer images of a PR pro-
tein. The codon insert (red) is superimposed on a PR protein
without the insert (blue). The resulting amino acid insert is
highlighted yellow.
CODON INSERT PROTEASE CLADE B HIV-1 549
References
1. Hammer SM, Eron JJ Jr, Reiss P, et al.: Antiretroviral treatment
of adult HIV infection: 2008 recommendations of the Interna-
tional AIDS Society-USA panel. JAMA 2008;300:555–570.
2. Larder BA, Darby G, and Richman DD: HIV with reduced
sensitivity to zidovudine (AZT) isolated during prolonged
therapy. Science 1989;243:1731–1734.
3. Richman DD: HIV chemotherapy. Nature 2001;410:995–1101.
4. Hirsch MS, Gunthard HF, Schapiro JM, et al.: Antiretroviral
drug resistance testing in adult HIV-1 infection: 2008 recom-
mendations of an International AIDS Society-USA panel. Clin
Infect Dis 2008;47:266–285.
5. Winters MA and Thomas MC: Insertion in the human im-
munodeficiency virus type 1 protease and reverse transcrip-
tase genes: Clinical impact and molecular mechanisms.
Antimicrobial Agents and Chemotherapy 2005;49:2575–2582.
6. Harrison GP, Mayo MS, Hunter E, and Lever AM: Pausing of
reverse transciptase on retroviral RNA templates is influ-
enced by secondary structures both 50 and 30 of catalytic site.
Nucleic Acids Res 1998;26:3433–3442.
7. Winters MA, Coolley KL, Girard YA, et al.: A 6 base-pair
insertion in the reverse transcriptase gene of HIV-1 confers
resistance to multiple nucleoside inhibitors. J Clin Invest
1998;102:1769–1775.
8. Kim EY, Winters MA, Kagan RM, and Merigan TC: Func-
tional correlates of insertion mutations in the protease gene of
human immunodeficiency virus type 1 isolates from patients.
J Virol 2001;75:11227–11233.
9. Kozisek M, Saskova KG, Rezacova P, et al.: Nintey-nine is
not enough: Molecular characterization of inhibito-resistant
human immunodeficiencey virus type 1 protease mutants
with insertions in the flap region. J Virol 2008;82:5869–
5878.
Address reprint requests to:
Davey Smith
University of California San Diego
9500 Gilman Dr. (MC-0679)
La Jolla, California 92093
E-mail: davey@ucsd.edu
550 JORDAN ET AL.
This article has been cited by:
1. Annemarie M.J. Wensing, Noortje M. van Maarseveen, Monique Nijhuis. 2010. Fifteen years of HIV Protease Inhibitors:
raising the barrier to resistance. Antiviral Research 85:1, 59-74. [CrossRef]
